ARSB and mucopolysaccharidosis type 6: Treatment with galsulfase, a recombinant form of ARSB, aims to prevent lysosomal accumulation of dermatan sulfate and chondroitin-4-sulfate and thus prevent MPS VI disease manifestations [28].